Resotran: Uses, Dosage & Side Effects

What Is Resotran and What Is It Used For?

Resotran contains the active substance prucalopride, a selective and high-affinity agonist of the serotonin type 4 (5-HT4) receptor. Prucalopride is the first commercially available representative of a new generation of highly selective 5-HT4 agonists that were developed specifically to avoid the off-target cardiovascular effects that led to the withdrawal of earlier, non-selective prokinetic drugs such as cisapride and tegaserod. Resotran is the brand name used in Canada and certain other markets; the same active ingredient is marketed as Resolor in the European Union and United Kingdom, and as Motegrity in the United States. It is licensed in many countries worldwide for the symptomatic treatment of chronic idiopathic constipation in adults.

Chronic idiopathic constipation is a functional gastrointestinal disorder characterized by persistent difficulty with bowel movements that cannot be explained by an underlying structural, endocrine, or drug-induced cause. Diagnostic criteria, such as the Rome IV criteria, require at least two of the following for the last three months with symptom onset at least six months prior to diagnosis: straining during more than 25% of defecations, lumpy or hard stools in more than 25% of defecations, a sensation of incomplete evacuation in more than 25% of defecations, a sensation of anorectal blockage in more than 25% of defecations, the need for manual maneuvers to facilitate defecation in more than 25% of defecations, and fewer than three spontaneous bowel movements per week. Many patients with CIC also experience bloating, abdominal discomfort, and reduced quality of life.

First-line management of chronic constipation focuses on dietary and lifestyle measures: increased fluid intake, a diet rich in soluble and insoluble fiber, regular physical activity, and establishing consistent toilet habits. When these measures are insufficient, laxatives are added, typically starting with osmotic agents (such as polyethylene glycol or lactulose) and, if needed, stimulant laxatives (such as senna or bisacodyl). Resotran is reserved for adults who have not achieved adequate relief despite appropriate trials of these conventional treatments. International guidelines, including those from the American College of Gastroenterology (ACG) and the European Society of Neurogastroenterology and Motility (ESNM), recognize prucalopride as an evidence-based second-line option for refractory CIC, supported by randomized controlled trials showing significant improvements over placebo in bowel movement frequency, symptom severity, and patient-reported quality of life.

Prucalopride has also been studied in other settings, including opioid-induced constipation, diabetic and idiopathic gastroparesis, and postoperative ileus. While these remain important areas of clinical research, such uses are considered off-label in most jurisdictions and should be discussed carefully with a specialist. In chronic idiopathic constipation specifically, the clinical development program included more than 2,500 patients across multiple pivotal trials, demonstrating a consistent treatment effect over placebo in terms of the co-primary endpoint of three or more spontaneous complete bowel movements per week during a 12-week treatment period.

What Should You Know Before Taking Resotran?

Contraindications

Certain medical situations make Resotran unsafe to use. These are called absolute contraindications, and in each of these cases the risk of harm outweighs any potential benefit. You should not take Resotran if any of the following apply to you:

• Hypersensitivity: Known allergy to prucalopride or to any of the inactive ingredients (excipients) listed in the product leaflet, including lactose monohydrate. Symptoms of allergy can include rash, itching, hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.
• Renal impairment requiring dialysis: Patients on hemodialysis or peritoneal dialysis should not take prucalopride, because the drug is eliminated primarily by renal excretion and clinical data in this population are insufficient.
• Intestinal perforation or obstruction: Known or suspected bowel perforation, mechanical obstruction, or ileus due to structural or functional disease of the gut wall. Stimulating peristalsis in a blocked intestine can cause serious harm.
• Severe inflammatory conditions: Severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon or toxic megarectum.

Warnings and Precautions

Beyond the absolute contraindications, there are situations in which Resotran can be used but requires extra caution, closer monitoring, or dose adjustment. Inform your doctor about your full medical history, all current medications (including over-the-counter drugs and herbal supplements), and any allergies before starting treatment.

The following patient groups and situations deserve particular attention:

• Severe renal impairment: Patients with a creatinine clearance below 30 mL/min (but not on dialysis) should receive a reduced dose of 1 mg once daily rather than the standard 2 mg. Regular monitoring of kidney function is advisable in patients at risk of renal decline.
• Severe hepatic impairment: In patients with severe liver disease (Child-Pugh class C), the starting dose should be reduced to 1 mg once daily; this can be titrated to 2 mg if tolerated and if additional therapeutic effect is needed.
• Elderly patients (over 65 years): Although the pharmacokinetics are only modestly affected by age, older patients often have reduced renal function and may be taking multiple other medications. Starting at 1 mg once daily and titrating upward according to tolerability is a reasonable approach.
• Cardiac disease: Prucalopride is considered cardiovascularly safer than older 5-HT4 agonists, but patients with significant structural heart disease, recent myocardial infarction, or uncontrolled arrhythmias should be evaluated carefully before treatment. Routine electrocardiographic monitoring is not required for most patients but may be considered in those with multiple cardiovascular risk factors.
• Psychiatric disorders: Post-marketing reports have described suicidal ideation and suicide attempts in patients taking prucalopride, although a causal link has not been established. Patients with a history of depression or other serious psychiatric illness should be monitored for new or worsening symptoms, and any suicidal thoughts should prompt immediate medical review and reassessment of treatment.
• Lactose intolerance: Resotran tablets contain lactose. Patients with the rare hereditary conditions of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.

Pregnancy and Breastfeeding

There are only limited data from the use of prucalopride in pregnant women. Animal studies have not demonstrated direct harmful effects with respect to reproductive toxicity at clinically relevant doses, but caution is warranted. Resotran is generally not recommended during pregnancy unless the potential benefit justifies the possible risk to the fetus. Cases of spontaneous abortion have been observed in some studies at doses higher than therapeutic exposure in animals, which underlines the importance of individual risk-benefit discussion with the prescribing physician.

Prucalopride is excreted into breast milk in animal studies, although the amount passing into human milk and any potential effect on breastfed infants is not fully characterized. A risk to the nursing infant cannot be excluded. Resotran should not be used during breastfeeding unless considered essential by a doctor. Women of childbearing potential should use effective contraception during treatment.

Driving and Operating Machinery

Resotran has a minor influence on the ability to drive and use machinery. Some patients experience dizziness and fatigue, especially during the first day of treatment. These effects are usually mild and transient. Caution is advised if these symptoms occur, particularly when driving, operating complex machinery, or performing tasks that require sustained concentration.

How Does Resotran Interact with Other Drugs?

Because prucalopride is not extensively metabolized by the major cytochrome P450 enzymes and is primarily eliminated unchanged by the kidneys, its potential for pharmacokinetic drug-drug interactions is relatively limited compared with many other medications. Nevertheless, certain combinations can either alter the exposure to prucalopride or modulate its clinical effect. Always provide your prescriber and pharmacist with a complete list of prescription medicines, over-the-counter products, vitamins, and herbal supplements before starting Resotran.

Major Interactions

Minor Interactions

In general, pharmacokinetic interaction studies have shown that prucalopride does not meaningfully alter the exposure of commonly coadministered drugs, including warfarin, digoxin, alcohol, paroxetine, and combined oral contraceptives. In turn, these medicines do not clinically significantly affect prucalopride exposure. The interaction profile is therefore considered favorable compared with many other gastrointestinal therapies, but individual review by a pharmacist or prescribing physician remains important, particularly for patients on multiple medications.

What Is the Correct Dosage of Resotran?

Resotran is prescribed and individualized by a physician based on your age, kidney and liver function, and overall clinical condition. The tablet should be swallowed whole with a glass of water; it can be taken with or without food, and at any time of the day. Consistency is more important than the specific time: choose a time you can remember each day. Do not chew, crush, or break the tablet, as this may affect the release characteristics and taste.

Adults

Elderly (Over 65 Years)

Renal Impairment

Hepatic Impairment

Children and Adolescents

Resotran is not recommended in children and adolescents under 18 years of age. A pediatric clinical trial did not demonstrate superiority over placebo in this population, and there is insufficient evidence to support its use for functional constipation in children. Pediatric constipation should be managed according to established guidelines, usually involving osmotic laxatives such as polyethylene glycol as first-line therapy, under the supervision of a pediatrician.

Missed Dose

If you forget to take a dose, skip the missed dose and take the next dose at your usual time the following day. Do not take a double dose to make up for a forgotten one. Because prucalopride has a long half-life (approximately 24 hours), missing a single dose is unlikely to have a major impact on your treatment, provided that doses are generally taken as prescribed.

Overdose

There is no specific antidote to prucalopride overdose. Management is supportive and symptomatic: replacement of fluid and electrolyte losses from diarrhea, cardiovascular and respiratory monitoring if clinically indicated, and symptomatic treatment of nausea or headache. In clinical studies of single doses up to 20 mg (ten times the recommended daily dose), side effects were qualitatively similar to those at therapeutic doses, and no serious consequences were observed.

What Are the Side Effects of Resotran?

Like all medicines, Resotran can cause side effects, although not everybody gets them. Most adverse reactions occur on the first day of treatment and reflect the expected pharmacological action of a prokinetic agent. They are usually mild to moderate in intensity and tend to resolve within a few days of continued treatment as the body adjusts. Persistent or severe side effects should always be discussed with your doctor.

The side-effect frequency categories used below follow the standard CIOMS/MedDRA convention adopted in the European and international regulatory literature:

• Very common: Affects more than 1 in 10 patients (≥10%)
• Common: Affects 1 in 10 to 1 in 100 patients (1–10%)
• Uncommon: Affects 1 in 100 to 1 in 1,000 patients (0.1–1%)
• Rare: Affects fewer than 1 in 1,000 patients (<0.1%)

The pattern of side effects observed in clinical trials is highly consistent across pivotal studies and real-world use. Headache and gastrointestinal symptoms such as nausea and abdominal cramping predominate on the first day of treatment. By the second day, their incidence is similar to placebo in most studies, reflecting a rapid tolerance effect. Diarrhea is a direct pharmacological consequence of enhanced colonic motility and is usually self-limiting or manageable by a temporary dose reduction. Severe diarrhea that persists despite stopping the medication, particularly if accompanied by fever, severe abdominal pain, or blood in the stool, warrants urgent medical review to rule out unrelated conditions such as infectious colitis or inflammatory bowel disease.

Post-marketing surveillance in Europe, North America, and Asia has not identified new safety concerns beyond those already documented in the Summary of Product Characteristics. However, vigilance is continuously maintained through regulatory pharmacovigilance programs. If you experience any side effect, including those not listed in this article or in the package leaflet, please report it to your doctor, pharmacist, or national reporting authority. Your reports contribute to ongoing safety monitoring and can help protect other patients.

How Should You Store Resotran?

Correct storage is important to maintain the quality, potency, and safety of the medicine throughout its shelf life. Follow these storage guidelines carefully:

• Temperature: Store below 30°C (86°F). The tablets do not require refrigeration and should not be frozen.
• Packaging: Keep Resotran in the original blister pack until use. The blister is designed to protect the tablets from moisture and light. Do not transfer the tablets to another container.
• Expiration date: Check the expiration date printed on the blister and the outer carton before use. The abbreviation “EXP” refers to the last day of the indicated month. Do not use the medicine beyond this date, even if the tablet looks unchanged.
• Child safety: Keep out of the sight and reach of children. Accidental ingestion of a large number of tablets could cause severe diarrhea, dehydration, and electrolyte disturbances in children.
• Unused or expired medicine: Do not dispose of medicines via household waste or wastewater. Instead, return unused or expired tablets to your local pharmacy. This helps protect the environment and prevents accidental misuse.
• Travel: When traveling, keep Resotran in its original packaging and carry it in hand luggage rather than checked baggage to protect it from extreme temperatures and to ensure you have access to your medication if luggage is delayed.

What Does Resotran Contain?

Active Ingredient

The active substance in Resotran is prucalopride, present as prucalopride succinate. Each 1 mg tablet contains 1 mg of prucalopride (equivalent to 1.321 mg of prucalopride succinate). Each 2 mg tablet contains 2 mg of prucalopride (equivalent to 2.642 mg of prucalopride succinate). Prucalopride is a dihydrobenzofurancarboxamide derivative that has been structurally optimized for high selectivity at 5-HT4 receptors over other serotonin receptor subtypes and human ether-a-go-go-related gene (hERG) potassium channels, giving the molecule its favorable safety profile relative to older agents in the same pharmacological class.

Inactive Ingredients (Excipients)

• Lactose monohydrate: Acts as a filler and provides bulk to the tablet. Important for patients with rare hereditary lactose intolerance disorders.
• Microcrystalline cellulose: A common pharmaceutical excipient used as a binder and filler.
• Colloidal anhydrous silica (silicon dioxide): Used as a glidant to improve flow during tablet manufacturing.
• Magnesium stearate: A lubricant that prevents the tablet material from sticking to manufacturing equipment.
• Film coating ingredients: Typically include hypromellose, lactose monohydrate, triacetin, titanium dioxide (E171), macrogol, and iron oxide colorants (such as red iron oxide for the 1 mg strength or yellow iron oxide for the 2 mg strength, depending on the manufacturer).

Appearance and Packaging

Resotran tablets are round, biconvex, film-coated tablets. The 1 mg tablet is usually white to off-white, while the 2 mg tablet is pink (appearance may differ between manufacturers and countries). Each tablet is debossed with a code identifying the manufacturer and strength. Tablets are supplied in aluminum foil blister packs, typically containing 7, 14, 28, 30, 50, 84, 90, or 100 tablets. Not all pack sizes may be marketed in every country.

Marketing Authorization Holder and Manufacturer

The marketing authorization for Resotran and its equivalents (Resolor in Europe, Motegrity in the United States) is held by Takeda Pharmaceuticals (previously Shire and Janssen, following corporate changes and licensing agreements). Generic prucalopride products have entered the market in several jurisdictions following expiration of primary patents, under separate brand names and with different excipients in some cases. Always check the specific package leaflet that accompanies your medication for exact manufacturer details and excipient information relevant to your product.